Nephron
Original Paper
Glomerular Filtration Rate and Urinary Albumin Excretion Rate in Systemic Lupus erythematosusCottiero R.A. · Madaio M.P. · Levey A.S.Division of Nephrology, New England Medical Center Hospital, Department of Medicine, Tufts University School of Medicine, Boston, Mass., USA
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Accepted: February 14, 1994
Published online: December 17, 2008
Issue release date: 1995
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0
ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)
For additional information: https://www.karger.com/NEF
Abstract
Our objective was to more precisely determine glomerular function in patients with systemic lupus erythematosus (SLE), without abnormalities in renal function, as determined by standard clinical laboratory tests. Our long-term goal is to identify patients during clinical quiescence who may be at high risk of developing progression to renal failure from lupus nephritis. We studied three groups of subjects: 8 patients with SLE and a history of nephritis, now in remission; 25 patients with SLE, without clinical evidence of nephritis, now or in the past; and 5 healthy women (normal controls). At the time of study, urinalysis, serum creatinine and 24-hour urine total protein excretion were within the normal range in each subject. We measured glomerular filtration rate (GFR) by 125I-iothalamate clearance, and albumin excretion rate (AER) by enzyme-linked immunosorbent assay (ELISA) in timed urine specimens. In addition, we compared 4-hour AER with 24-hour AER and spot urine albumin/creatinine ratio (A/C). Among patients with a history of nephritis now in remission, mean GFR was slightly but not significantly lower and mean AER was elevated (p < 0.03). Among patients with SLE without a history of nephritis, mean GFR was normal, but the variance in GFR was greater than normal (p < 0.005). Seven patients without nephritis (28%) had either hyperfiltration or hypofiltration. Mean AER was normal, but 3 other patients (12%) had elevated AER. There was no correlation of GFR and AER among patients in either group. Correlations (r) of spot urine A/C and 24-hour AER with 4-hour AER were 0.93 (p < 0.001) and 0.88 (p < 0.00l), respectively. We conclude that most patients with SLE and a history of nephritis now in remission have persistent abnormalities in glomerular function, and as many as 40% of patients without a history of nephritis also have subtle defects in glomerular function. Whether these abnormalities in glomerular function define a subset of patients at higher risk of developing renal failure, independent of disease activity, requires further study. Spot urine A/C is a valid measure of AER in SLE.
© 1995 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Accepted: February 14, 1994
Published online: December 17, 2008
Issue release date: 1995
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0
ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)
For additional information: https://www.karger.com/NEF
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
